MedTrace Logo

Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

NCT00175019 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1086

Last updated 2010-07-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.

Conditions

Interventions

DRUG

Febuxostat

Febuxostat 80 mg, tablets, orally, once daily.

DRUG

Febuxostat

Febuxostat 120 mg, tablets, orally, once daily.

DRUG

Allopurinol

Allopurinol 100 mg or 300 mg, tablets, orally, once daily.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2007-02-28
Completion
2007-02-28

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00175019 on ClinicalTrials.gov